Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts.

The conjugation of antineoplastic drugs to monoclonal antibodies reactive with tumor associated antigens conveys selective cytotoxicity, overcoming the systemic toxicities caused by drugs during standard chemotherapy. 2'-Deoxy-5-fluorouridine, a more potent derivative of 5-fluorouracil, is an antimetabolite which exerts its cytotoxic action by inhibiting the enzyme thymidylate synthetase and as a result inhibits DNA synthesis. 2'-Deoxy-5-fluorouridine was successfully conjugated to anti-Ly-2.1 reactive with the murine thymoma ITT(1)75NS E3, I-1, and 250-30.6 reactive with human colon cancer cells using the active ester of 2'-deoxy-5-fluoro-3'-O-succinoyluridine (5FdUrdsucc). In vitro, 5Fd-Urdsucc-anti-Ly-2.1 was selectively cytotoxic against ITT(1)75NS E3 murine thymoma cells at nanomolar concentrations. The human colon carcinoma cell LIM1899 was inhibited by 5FdUrdsucc-I-1 conjugates in the range of 10(-7)-10(-8) M, as were Colo 205 cells by 5FdUrdsucc-250-30.6 conjugates. In vivo, 5FdUrdsucc conjugates were more effective than equivalent amounts of free 5FdUrdsucc. Against the ITT(1)75NS E3 murine thymoma, a single dose of 100 micrograms (5FdUrdsucc equivalents) 5FdUrdsucc-anti-Ly-2.1 resulted in 85% tumor inhibition compared to mean tumor size of control mice. Irrelevant 5FdUrdsucc conjugates failed to inhibit tumor growth. Multiple doses of 5FdUrdsucc-I-1 conjugate produced 50% growth inhibition of the moderately differentiated tumor LIM1899. In contrast, the human colon carcinoma Colo 205 was relatively resistant to free 5FdUrdsucc and 5FdUrdsucc-250-30.6 conjugates.

[1]  G. Pietersz,et al.  In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates. , 1991, Bioconjugate chemistry.

[2]  A. Brill,et al.  Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer. , 1991, Cancer research.

[3]  R. Reisfeld,et al.  Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. , 1990, Bioconjugate chemistry.

[4]  J. Double,et al.  Therapeutic index: a vital component in selection of anticancer agents for clinical trial. , 1989, Journal of the National Cancer Institute.

[5]  I. Pastan,et al.  Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. , 1989, Cancer research.

[6]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[7]  Y. Rustum,et al.  Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Slevin,et al.  Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. , 1987, Cancer research.

[9]  M. Wilchek,et al.  The covalent linking of two nucleotide analogues to antibodies. , 1985, Journal of medicinal chemistry.

[10]  P. Engstrom,et al.  Chemotherapy of advanced colorectal carcinoma: Fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin A phase III trial by the Eastern Cooperative Oncology Group (EST 1278) , 1984, American journal of clinical oncology.

[11]  P. Hogarth,et al.  Alloantigenic phenotype of radiation-induced thymomas in the mouse. , 1982, Journal of the National Cancer Institute.

[12]  J. Laskin,et al.  Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. , 1981, Cancer research.

[13]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.